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Morphine is the gold standard opioid to treat moderate to severe pain. Morphine-6-glucuronide (M6G) is an 
active metabolite and contributes to the effect of morphine [1]. The pharmacokinetics (PK) of morphine and 
M6G are associated with large inter-individual variability, which makes optimal dose selection challenging, 
especially in populations such as neonates and patients with renal impairment [2].  
[1] Binning, A.R., Przesmycki, K., Sowinski, P., Morrison, L.M., Smith, T.W., Marcus, P., Lees, J.P., Dahan, A., 2011. A randomised controlled trial on the efficacy and side-effect profile (nausea/
vomiting/sedation) of morphine-6-glucuronide versus morphine for post-operative pain relief after major abdominal surgery. Eur. J. Pain 15, 402-408. 
[2] Somogyi, A.A., Barratt, D.T., Coller, J.K., 2007. Pharmacogenetics of opioids. Clin. Pharmacol. Ther. 81, 429-444. 
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RESEARCH PARTNERS 
 
Mean transit time 
0.729 h Oral solution, oral immediate-release tablet, and rectal solution 
14.6 h Oral modified-release tablet 
0.310 h Subcutaneous injection 
Bioavailability 
14.4% Oral solution and oral immediate-release tablet 
18.8% Oral modified-release tablet and rectal solution 
Systemic metabolism 
12.8% All 
First-pass metabolism 
20.8% Oral solution, oral immediate-release tablet, oral modified-
release tablet, and rectal solution 
 
 Morphine and M6G data from 22 studies, 686 subjects 
 Various administration routes 
 Healthy volunteers, preterm neonates, and patients 
with e.g. renal impairment 
 NONMEM 7.3.0, PsN, and Pirana 
 Sequential modelling of morphine and M6G data 
METHODS  
 
 Two compartment morphine and M6G models 
 Two transit compartment absorption for morphine 
(oral, rectal, and subcutaneous route) 
 Systemic and first-pass metabolism of morphine to 
M6G described 
 Several covariates identified including age on 
morphine clearance, and creatinine clearance on M6G 
clearance 
RESULTS 
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 M6G concentration-time data from 4 studies 
Morphine concentration-time data from 18 studies 
M6G concentration-time data from 14 studies 
 
The aims of this study were to develop a combined 
morphine and M6G PK metamodel in neonates and 
adults, identify covariates that explain some of the large 
variability, and describe the formation of M6G after 
administration of morphine through different routes. 
AIMS 
 
 Some of the large inter-individual variability in 
morphine and M6G PK was explained with covariates 
 Individual morphine and M6G concentrations can be 
predicted in the shiny application 
CONCLUSION 
Parameter Covariate Relationship Equation 
Morphine clearance Postmenstrual age Sigmoidal 
 
  Age (adults) Power 
 
M6G clearance Creatinine clearance Power 
 
Morphine and M6G 
central volume 
Venous sampling site Linear 
 
All clearances and 
volume 
Body weight 
Power, fixed 
exponent (0.75 
for clearances, 1 
for volumes) 
 
PHARMACOKINETIC MODEL 
 
Link to shiny app: https://unicph.shinyapps.io/MorphineMetamodel/  
Shiny App 
